|
1. |
Armstrong DG. The Efficacy of Apligraf in the Treatment of Diabetic Foot Ulcers. Plast. Reconstr. Surg. 2006; 117(Suppl.): 158S-159S. |
|
2. |
Atillasoy E. The Safety and Efficacy of Graftskin (Apligraf) in the Treatment of Venous Leg Ulcers: A Multicenter, Randomized, Controlled Clinical Trial. Wounds. 2000; 12(5 Suppl A):20A-26A. |
|
3. |
Becker HD, Beckert S and Coerper S. Skin Grafting of Venous Ulcers: A Review of its Current Role Int J Low Extrem Wounds. 2002; 1: 236. |
|
4. |
Bello YM, Falabella AF. The role of graftskin (Apligraf) in difficult-to-heal venous leg ulcers. J Wound Care. 2002; 11(5):182-3. |
|
5.
|
Boulton Andrew JM, Kirsner Robert S, Vileikyte Loretta. Neuropathic Diabetic Foot Ulcers. New Engl J Med. 2004; 351:48-55. |
|
6. |
Brem H. Protocol for the Successful Treatment of Venous Ulcers. Amer. J. of Surg. 2004; 188(Suppl. 1A):1S-8S. |
|
7. |
Brem Harold, Sheehan Peter, Boulton Andrew JM. Protocol for Treatment of Diabetic Foot Ulcers. American Journal of Surgery. 2004; 187(May Supplement): 1S-10S. |
|
8. |
Brem H, Young J, Isaacs C, Tomic-Canic M, Ehrlich Paul. Clinical Efficacy and Mechanisms of Bilayered Living Human Skin Equivalent (HSE) in Treatment of Diabetic Foot Ulcers. Surgical Technology International XI. May 2003; 23-31. |
|
9. |
Brem H, Balledux J, Sukkarieh T, Cason, P and Falanga V. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg. 2001; 27:915-919. |
|
10. |
Cavorsi JP. Evidence-Based Wound Care Standards in the Clinical Setting: Applying the Knowledge to Real-World Practice. Supplement to Wounds September 2007: 9-12. |
|
11.
|
Cavorsi J, et al. Best Practices Algorithms for the use of a Bilayered Living Cell Therapy Apligraf in the Treatment of Lower Extremity Ulcers. Wound Rep Reg. 2006; 14:102–109. |
|
12.
|
Chow I, Lemos EV, Einarson TR. Management and prevention of diabetic foot ulcers and infections: a health economic review. Pharmacoeconomics. 2008; 26(12):1019-35. |
|
13. |
DeCarbo WT. Bilayered Bioengineered Skin Substitute to Augment Wound Healing. Foot & Ankle Specialist Dec 2009 2(6): 303-305. |
|
14. |
DeCarbo WT. Apligraf: Bilayered Skin Substitute to Augment Wound Healing of Chronic Wounds in Diabetic Patients. Foot & Ankle Specialist Dec 2009 2(6): 299-302. |
|
15. |
Edmonds M. Apligraf in the Treatment of Neuropathic Diabetic Foot Ulcers. International Journal of Lower Extremity Wounds. 2009; 8(1):11-18. |
|
16. |
Fahey C. Experience with a new human skin equivalent for healing venous leg ulcers. J Vasc Nurs. 1998; 16(1):11-5. |
|
17. |
Falanga, V., et al: Wound Bed Score and its Correlation with Healing of Chronic Wounds. Dermatologic Therapy. 2006; 19:383-390. |
|
18. |
Falanga V. Bioengineered skin. Wounds. 2000; 12(6 Suppl B):99B-105B. |
|
19.
|
Falanga V, Sabolinski ML. Prognostic factors for healing of venous and diabetic ulcers. Wounds. 2000; 12(5 Suppl A):42A-46A. |
|
20. |
Falanga V and Sabolinski M. A Bilayered Living Skin Construct (Apligraf®) Accelerates Complete Closure of Hard-to-Heal Venous Ulcers. Wound Repair and Regeneration. 1999; 7(4):201-207. |
|
21. |
Falanga V. How to Use Apligraf to Treat Venous Ulcers. Skin & Aging, February 1999:30-36. |
|
22. |
Falanga, V., et al: Rapid Healing of Venous Ulcers and Lack of Clinical Rejection with an Allogeneic Cultured Human Skin Equivalent. Arch. Dermatol. 1998; 134: 293-300. |
|
23. |
Farah RS, Davis MD. Venous leg ulcerations: a treatment update. Curr Treat Options Cardiovasc Med. 2010 Apr;12(2):101-16. |
|
24. |
Fivenson D, Scherschun L. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers. Int J Dermatol. 2003 Dec; 42(12):960-5. |
|
25. |
Hanft JR and Henao M. Current concepts with bioengineered alternative tissues. Podiatry Today. 2010 July: 60-65. |
|
26. |
Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care. Br J Nurs. 2000; 9(19 Suppl): S6, S8, S10 passim. |
|
27. |
Hunt NA, Liu GT, Lavery LA. The economics of limb salvage in diabetes. Plast Reconstr Surg. 2011 Jan;127 Suppl 1:289S-295S. |
|
28. |
Jones JE, Nelson EA. Skin grafting for venous leg ulcers. Cochrane Database of Systematic Reviews 2007, Issue 2, Art. No.:CD001737 |
|
29.
|
Karr JC. Retrospective Comparison of Diabetic Foot Ulcer and Venous Stasis Ulcer Healing Outcome Between a Dermal Repair Scaffold (PriMatrix) and a Bilayered Living Cell Therapy (Apligraf). Adv Skin Wound Care. 2011 Mar: 119-125. |
|
30.
|
Kerstein Morris D., et al: Development of a Severity Scale for Evaluating the Need for Graftskin in Nonhealing Ulcers. Adv in Skin Wound Care. 2002; 15(2):66-71. |
|
31. |
Kim P, Heilala M, Steinberg J, Weinraub G. Bioengineered alternative tissues and hyperbaric oxygen in lower extremity wound healing. Clin Podiatr Med Surg. 2007 Jul;24(3):529-46. |
|
32. |
Kirsner RS, Warriner R, Michela M, Stasik L and Freeman K. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. 2010 Aug;146(8):857-862. |
|
33.
|
Kirsner RS. The Science of Bilayered Cell Therapy. Supplement to Wounds Sept 2005. |
|
34.
|
Kirsner RS, Fastenau J, Falabella A, Valencia I, Long R, Eaglstein WH. Clinical and economic outcomes with Graftskin for hard-to-heal venous leg ulcers: a single-center experience. Dermatol Surg. 2002; 28:81-82 |
|
35. |
Kirsner R, Falanga V, Fivenson D, Thibodeaux K, Cavorsi J, de la Pava D, Brem H, Golomb CA. Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes. Wounds. 1999; 11(6):137-144. |
|
36. |
Kuhn C, Angehrn F. Use of high-resolution ultrasound to monitor the healing of leg ulcers: a prospective single-center study. Skin Research and Technology. 2009: 1–7. |
|
37. |
Landsman AS, et al. A Retrospective Clinical Study of 188 Consecutive Patients to Examine the Effectiveness of a Biologically Active Cryopreserved Human Skin Allograft (Theraskin) on the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Foot Ankle Spec 2011 4: 29 originally published online 6 December 2010 |
|
38. |
Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research. 2009, 9:115. |
|
39. |
MacKay G. Bioactive wound healing, bioaesthetics and biosurgery: three pillars of product development. Interview with Geoff MacKay. Regen Med. 2006 Mar; 1(2):169-74. |
|
40. |
Mason, C and Manzotti, E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med. 2010; 5(3): 307–313. |
|
41. |
Masseth R. Apligraf: A Promising New Wound Care Treatment for the 21st Century. J of National Assoc. Ortho Tech. Spring 2002:22-25. |
|
42. |
Mathias SD, Prebil LA, Boyko WL, Fastenau J. Health-related quality of life in venous leg ulcer patients successfully treated with Apligraf: a pilot study. Adv Skin Wound Care. 2000; 13(2):76-8. |
|
43. |
Moneta G. Graftskin (Apligraf) in the treatment of venous leg ulcer: optimal application techniques. Wounds. 2000; 12(5 Suppl A):27A-32A. |
|
44. |
Moneta G. et al, Skin Substitute Consensus Development Panel. Nonoperative Management of Venous Leg Ulcers: Evolving Role of Skin Substitutes. Vascular Surgery.1999; 33(2). |
|
45. |
Nelson EA, Jones J. Venous leg ulcers. Clinical Evidence 2008;09:1902 |
|
46. |
Noel B. Economic assessment of Apligraf for the treatment of venous leg ulcers. Wound Repair Regen. 2001; 9(1): 60. |
|
47. |
O’Donnell TF, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg. 2006; 44:1118-25. |
|
48. |
Pham, H.T., et al: Evaluation of a Human Skin Equivalent for the Treatment of Diabetic Foot Ulcers in a Prospective, Randomized, Clinical Trial. Wounds. 1999; 11(4): 79-86. |
|
49. |
Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J, Falanga V. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol. 2002; 138(8):1079-81. |
|
50. |
Phillips TJ. New Skin for Old. Arch of Dermatol. 1998; (134):344-349. |
|
51. |
Plotner AN and Mostow EN. A review of bioactive materials and chronic wounds. Cutis. 2010; 85:259-266. |
|
52. |
Pollak R. Use of Graftskin (Apligraf) in diabetic foot ulcers: case presentations. Wounds. 2000; 12(5 Suppl A):37A-41A. |
|
53. |
Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003; 21(16):1171-83. |
|
54. |
Saap Liliana J., Falanga Vincent. Debridement Performance index and its correlation with complete closure of diabetic foot ulcers. Wound Rep Reg. 2002; 10: 354-359. |
|
55. |
Sabolinski ML and Bilbo PR. The Clinical Experience of Bioengineered Skin Products. In Falanga, V., eds. Cutaneous Wound Healing. Martin Dunitz; 2001: 411-431. |
|
56. |
Sabolinski ML, Veves A. Graftskin (Apligraf) in neuropathic diabetic foot ulcers. Wounds. 2000; 12(5 Suppl A):33A-36A. |
|
57. |
Sabolinski, M.L., et al: Cultured Skin as a Smart Material for Healing Wounds: Experience in Venous Ulcers. Biomaterials 17: 311-320, 1996 |
|
58. |
Samies, JH. Infection and Pain Control in Wound Care: Getting the Most out of Bilayered Living Cell Therapy. Evidence-Based Wound Care Standards in the Clinical Setting: Applying the Knowledge to Real-World Practice. Supplement to Wounds. September 2007: 9-12. |
|
59. |
Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg. 2002; 28(8):698-703. |
|
60. |
Schonfeld, W.H., et al: An economic assessment of Apligraf for the treatment of hard-to-heal venous leg ulcers. Wound Repair and Regeneration. 2000: 8(4): 251-257. |
|
61. |
Shafritz R. Combining Bilayered Living Cell Therapy with Minimally Invasive Vein Surgery: Current Treatment Strategies for Venous Ulcers. Supplement to Vascular Disease Management. March/April 2007: 4-10. |
|
62.
|
Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P. Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 2001; 47(8): 36-46. |
|
63. |
Sibbald RG. Apligraf Living Skin Equivalent for Healing Venous and Chronic Wounds. Journal of Cutaneous Medicine and Surgery. 1998; 3(Suppl 1): S1-24-S1-28. |
|
64. |
Snyder R. Tips on Using Apligraf. Podiatry Management. 2008: August:169-170. |
|
65. |
Snyder R. The Quality of Care and Economic Benefits of Utilizing Apligraf in Clinical Practice. Podiatry Management. 2008: January:201-208. |
|
66. |
Steinberg JS, Edmonds M, Hurley DP, King WN. Confirmatory Data from EU Study Supports Apligraf for the Treatment of Neuropathic Diabetic Foot Ulcers. J Am Podiatr Med Assoc. 2010; 100(1):73. |
|
67. |
Steinberg J. Putting Bilayered Cell Therapy to Use. Supplement to Wounds. 2005; September. |
|
68. |
Steinberg J, et al: A Cost Analysis of a Living Skin Equivalent in the Treatment of Diabetic Foot Ulcers. Wounds. 2002; 14(4):142-149. |
|
69. |
Steinberg J and Ho T. Apligraf: how effective is it? Podiatry Today. 2001; September. |
|
70. |
Steinberg J. How you can use Apligraf to treat diabetic foot ulcers. Podiatry Today. 2000; September. |
|
71. |
Streit M, Braathen LR. Apligraf – a living human skin equivalent for the treatment of chronic wounds. Int J Artif Organs. 2000 Dec; 25(12):831-3. |
|
72. |
Teng YJ, et al: Bioengineered skin in diabetic foot ulcers. Diabetes Obes Metab. 2010 Apr; 12(4):307-15. |
|
73. |
Veves A., et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24(2):290-295. |
|
74. |
White R, McIntosh C. A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments. J Wound Care. 2009 Aug; 18(8):335-41. Review. |
|
75. |
Woo K, Ayello EA, Sibbald RG. The Edge Effect: Current Therapeutic Options to Advance the Wound Edge. Advances in Skin & Wound Care. 2007; 20:99-117, quiz 118-9. |
